Table 4.
Baseline Characteristics of SCORE2 Participants1
| Randomized Treatment Assignment | Disease Type | Anti-VEGF Treatment Prior to SCORE2 | Total | ||||
|---|---|---|---|---|---|---|---|
| Characteristic2 | Aflibercept | Bevacizumab | CRVO | HRVO | No | Yes | |
| Number of participants | 180 | 182 | 307 | 55 | 241 | 121 | 362 |
| Demographic Characteristics | |||||||
| Age (years) – mean (SD) | 69(11) | 69(13) | 69(12) | 70(13) | 68(12) | 71(11) | 69(12) |
| < 50 (%) | 7(3.9) | 15(8.2) | 18(5.9) | 4(7.3) | 18(7.5) | 4(3.3) | 22(6.1) |
| 50-<60 (%) | 28(15.6) | 26(14.3) | 48(15.6) | 6(10.9) | 38(15.8) | 16(13.2) | 54(14.9) |
| 60-<70 (%) | 59(32.8) | 48(26.4) | 95(30.9) | 12(21.8) | 74(30.7) | 33(27.3) | 107(29.6) |
| 70-<80 (%) | 58(32.2) | 52(28.6) | 92(30.0) | 18(32.7) | 65(27.0) | 45(37.2) | 110(30.4) |
| ≥ 80 (%) | 28(15.6) | 41(22.5) | 54(17.6) | 15(27.3) | 46(19.1) | 23(19.0) | 69(19.1) |
| Women (%) | 82(45.6) | 75(41.2) | 136(44.3) | 21(38.2) | 96(39.8) | 61(50.4) | 157(43.4) |
| White (%) | 131(72.8) | 145(79.7) | 246(80.1) | 30(54.5) | 186(77.2) | 90(74.4) | 276(76.2) |
| Black (%) | 28(15.6) | 26(14.3) | 33(10.7) | 21(38.2) | 35(14.5) | 19(15.7) | 54(14.9) |
| Other (%) | 21(11.7) | 11(6.0) | 28(9.1) | 4(7.3) | 20(8.3) | 12(9.9) | 32(8.8) |
| Not Hispanic or Latino (%) | 164(91.1) | 160(87.9) | 274(89.3) | 50(90.9) | 214(88.8) | 110(90.9) | 324(89.5) |
| Study Eye Characteristics | |||||||
| E-ETDRS visual acuity letter score – mean (SD) | 50(15) | 50(15) | 50(15) | 54(14) | 50(15) | 50(15) | 50(15) |
| 59–73 (20/40 to 20/63) (%) | 66(36.7) | 67(36.8) | 108(35.2) | 25(45.5) | 88(36.5) | 45(37.2) | 133(36.7) |
| 49–58 (20/80 to 20/100) (%) | 43(23.9) | 42(23.1) | 70(22.8) | 15(27.3) | 58(24.1) | 27(22.3) | 85(23.5) |
| 19–48 (20/125 to 20/400) (%) | 71(39.4) | 73(40.1) | 129(42.0) | 15(27.3) | 95(39.4) | 49(40.5) | 144(39.8) |
| Duration of macular edema (months) – mean (SD) | 8(17) | 5(10) | 7(14) | 3(10) | 1(3) | 18(19) | 6(14) |
| Missing | 1(0.6) | 1(0.5) | 2(0.7) | 0(0.0) | 0(0.0) | 2(1.7) | 2(0.6) |
| <3 (%) | 114(63.3) | 129(70.9) | 199(64.8) | 44(80.0) | 230(95.4) | 13(10.7) | 243(67.1) |
| 3 – 6 (%) | 18(10.0) | 11(6.0) | 25(8.1) | 4(7.3) | 8(3.3) | 21(17.4) | 29(8.0) |
| 7 – 12 (%) | 17(9.4) | 17(9.3) | 30(9.8) | 4(7.3) | 2(0.8) | 32(26.4) | 34(9.4) |
| >12 (%) | 30(16.7) | 24(13.2) | 51(16.6) | 3(5.5) | 1(0.4) | 53(43.8) | 54(14.9) |
| OCT central subfield (microns) – mean (SD) | 665(220) | 690(238) | 691(230) | 606(213) | 689(229) | 655(231) | 678(230) |
| Prior anti-VEGF treatment | 65(36.1) | 56(30.8) | 108(35.2) | 13(23.6) | - | 121(100) | 121(33.4) |
| HRVO | 24(13.3) | 31(17.0) | - | 55(100) | 42(17.4) | 13(10.7) | 55(15.2) |
| Lens Status | |||||||
| Cataract extraction | 43(23.9) | 55(30.2) | 83(27.0) | 15(27.3) | 57(23.7) | 41(33.9) | 98(27.1) |
| Natural lens, history of cataract | 108(60.0) | 95(52.2) | 170(55.4) | 33(60.0) | 137(56.8) | 66(54.5) | 203(56.1) |
| Natural lens, no history of cataract | 29(16.1) | 32(17.6) | 54(17.6) | 7(12.7) | 47(19.5) | 14(11.6) | 61(16.9) |
| Other Clinical Characteristics | |||||||
| Diabetes mellitus (%) | |||||||
| Type 1 | 1(0.6) | 0(0.0) | 1(0.3) | 0(0.0) | 0(0.0) | 1(0.8) | 1(0.3) |
| Type 2 | 54(30.0) | 59(32.4) | 95(30.9) | 18(32.7) | 74(30.7) | 39(32.2) | 113(31.2) |
| Hypertensive (%) | 140(77.8) | 138(75.8) | 236(76.9) | 42(76.4) | 184(76.3) | 94(77.7) | 278(76.8) |
| Coronary artery disease (%) | 26(14.4) | 29(15.9) | 48(15.6) | 7(12.7) | 34(14.1) | 21(17.4) | 55(15.2) |
| NEI-VFQ-25 overall score | 77(15) | 77(17) | 77(16) | 78(16) | 76(16) | 78(16) | 77(16) |
1
P-values that are less than 0.05, either before adjustment (comparing treatment groups), or after adjustment (comparing CRVO vs HRVO, or prior versus no prior anti VEGF) are highlighted
2
Mean (Std Dev) unless otherwise noted